ATE520025T1 - Test für morbus-parkinson-therapeutika - Google Patents
Test für morbus-parkinson-therapeutikaInfo
- Publication number
- ATE520025T1 ATE520025T1 AT06848996T AT06848996T ATE520025T1 AT E520025 T1 ATE520025 T1 AT E520025T1 AT 06848996 T AT06848996 T AT 06848996T AT 06848996 T AT06848996 T AT 06848996T AT E520025 T1 ATE520025 T1 AT E520025T1
- Authority
- AT
- Austria
- Prior art keywords
- parkinson
- test
- parkin
- disease therapeutics
- disease
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/25—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving enzymes not classifiable in groups C12Q1/26 - C12Q1/66
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
- G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/10—Screening for compounds of potential therapeutic value involving cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2835—Movement disorders, e.g. Parkinson, Huntington, Tourette
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Food Science & Technology (AREA)
- Pathology (AREA)
- Genetics & Genomics (AREA)
- General Physics & Mathematics (AREA)
- Toxicology (AREA)
- Cell Biology (AREA)
- Wood Science & Technology (AREA)
- Biophysics (AREA)
- Tropical Medicine & Parasitology (AREA)
- General Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Enzymes And Modification Thereof (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US74996405P | 2005-12-12 | 2005-12-12 | |
| PCT/US2006/047515 WO2007089334A2 (en) | 2005-12-12 | 2006-12-12 | Assay for parkinson's disease therapeutics and enzymatically active parkin preparations useful therein |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE520025T1 true ATE520025T1 (de) | 2011-08-15 |
Family
ID=38179819
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT06848996T ATE520025T1 (de) | 2005-12-12 | 2006-12-12 | Test für morbus-parkinson-therapeutika |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US20070212679A1 (de) |
| EP (1) | EP1969367B1 (de) |
| JP (1) | JP2009519040A (de) |
| AT (1) | ATE520025T1 (de) |
| CA (1) | CA2632657A1 (de) |
| WO (1) | WO2007089334A2 (de) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8017348B1 (en) | 2005-12-12 | 2011-09-13 | Elan Pharma International Limited | Assay for Parkinson's Disease therapeutics |
| WO2007089334A2 (en) * | 2005-12-12 | 2007-08-09 | Elan Pharmaceuticals, Inc. | Assay for parkinson's disease therapeutics and enzymatically active parkin preparations useful therein |
| SI2170888T1 (sl) | 2007-06-29 | 2015-10-30 | Gilead Sciences, Inc. | Purinski derivati in njihova uporaba kot modulatorjev receptorja tipa toll-7 |
| JP2011514148A (ja) * | 2008-01-31 | 2011-05-06 | エラン ファーマ インターナショナル リミテッド | パーキンソン病の予防および処置用の候補化合物を同定するための熱変性スクリーニングアッセイ |
| JP2011528908A (ja) * | 2008-07-25 | 2011-12-01 | プロジェンラ インク． | ユビキチンリガーゼのモジュレーターの特定法 |
| WO2010040842A1 (en) * | 2008-10-09 | 2010-04-15 | Universitat Autònoma De Barcelona | Linking protein aggregation and yeast survival |
| AU2009333559B2 (en) | 2008-12-09 | 2015-03-12 | Gilead Sciences, Inc. | Modulators of toll-like receptors |
| MX2012004706A (es) | 2009-10-22 | 2012-06-08 | Gilead Sciences Inc | Derivados de purina o deazapurina utiles para el tratamiento de (inter alia) infecciones virales. |
| TWI733652B (zh) | 2014-07-11 | 2021-07-21 | 美商基利科學股份有限公司 | 用於治療ＨＩＶ之ｔｏｌｌ樣受體調節劑 |
| JP2017526730A (ja) | 2014-09-16 | 2017-09-14 | ギリアード サイエンシーズ， インコーポレイテッド | Ｔｏｌｌ様受容体モジュレーターの固体形態 |
| JP6814991B2 (ja) * | 2016-02-01 | 2021-01-20 | 学校法人順天堂 | パーキン活性化剤のスクリーニング法 |
| KR20220011685A (ko) | 2019-05-22 | 2022-01-28 | 길리애드 사이언시즈, 인코포레이티드 | Tlr7 조절 화합물과 hiv 백신의 조합 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5925323A (ja) * | 1982-03-03 | 1984-02-09 | 鐘淵化学工業株式会社 | プテリン誘導体からなる脳内神経伝達物質の関わる疾病の治療剤 |
| EP1262557B1 (de) * | 2000-02-24 | 2006-10-18 | Boehringer Ingelheim International GmbH | Das parkin-protein als ubiquitinligase |
| EP1373515A2 (de) * | 2001-03-29 | 2004-01-02 | Nsgene A/S | Mittel zur hemmung der proteolyse von parkin |
| JP2003018992A (ja) * | 2001-06-28 | 2003-01-21 | Inst Of Physical & Chemical Res | Ｐａｅｌ受容体、Ｐａｅｌ受容体発現細胞および動物、ならびにパーキンソン病治療薬のスクリーニング法 |
| US7070940B2 (en) * | 2002-07-18 | 2006-07-04 | Aventis Pharma S.A. | Method for determining the ability of a compound to modify the interaction between parkin and the p38 protein |
| US20060159681A1 (en) * | 2004-12-14 | 2006-07-20 | Functional Neuroscience Inc. | Compositions and methods to inhibit cell loss by using inhibitors of BAG |
| WO2007089334A2 (en) * | 2005-12-12 | 2007-08-09 | Elan Pharmaceuticals, Inc. | Assay for parkinson's disease therapeutics and enzymatically active parkin preparations useful therein |
-
2006
- 2006-12-12 WO PCT/US2006/047515 patent/WO2007089334A2/en not_active Ceased
- 2006-12-12 US US11/638,242 patent/US20070212679A1/en not_active Abandoned
- 2006-12-12 EP EP06848996A patent/EP1969367B1/de active Active
- 2006-12-12 AT AT06848996T patent/ATE520025T1/de not_active IP Right Cessation
- 2006-12-12 JP JP2008545762A patent/JP2009519040A/ja active Pending
- 2006-12-12 CA CA002632657A patent/CA2632657A1/en not_active Abandoned
- 2006-12-12 US US12/096,890 patent/US20090317825A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20090317825A1 (en) | 2009-12-24 |
| JP2009519040A (ja) | 2009-05-14 |
| EP1969367B1 (de) | 2011-08-10 |
| EP1969367A2 (de) | 2008-09-17 |
| CA2632657A1 (en) | 2007-08-09 |
| WO2007089334A3 (en) | 2008-01-10 |
| WO2007089334A2 (en) | 2007-08-09 |
| US20070212679A1 (en) | 2007-09-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0513477A (pt) | composições e processos de uso de proteìna 4 semelhante a angiotensina | |
| ES2353814T3 (es) | Proteinas n-glicosiladas recombinantes de celulas procariotas. | |
| MX358705B (es) | Agentes de union de esclerostina. | |
| ATE405650T1 (de) | Produktion von ganzen antikörpern in prokaryontischen zellen | |
| BR0011838B1 (pt) | elemento de sela e estrutura de misturador estático. | |
| MA30474B1 (fr) | Formulations de molecule peptide(s) -anticorps therapeutique lyophilisee. | |
| CL2011000010A1 (es) | Anticuerpo monoclonal anti-peptido beta-amiloide; polinucleotido que lo codifica; hibridoma; metodo de produccion; composicion que lo comprende; uso para tratar enfermedades relacionadas con proteinas amiloides; metodo de diagnostico de las mismas; y kit que lo comprende. | |
| MA29836B1 (fr) | Proteines de fusion avec l'albumine | |
| BRPI0516857A (pt) | dispositivos biomédicos que contêm copolìmeros de bloco anfifìlico | |
| DE602008005596D1 (de) | Biologisch aktive proteine mit erhöhter in-vivo- und/oder in-vitro-stabilität | |
| NO20043245L (no) | Bindingsproteiner som biosensorer | |
| CY1108689T1 (el) | Ολιγοπεπτιδια για την ελαττωση αυξημενης συγκεντρωσεως της ουριας στο αιμα | |
| ATE485359T1 (de) | Verwendung von grenzflächenaktiven, nicht- enzymatischen proteinen für die textilwäsche | |
| AR113492A2 (es) | Furina recombinante libre de proteínas sustancialmente animal y métodos para producirla | |
| MX2009002787A (es) | Composiciones y métodos para prevenir el cáncer con cupredoxinas. | |
| ATE463512T1 (de) | Identifizierung und charakterisierung von funktionsblockierenden anti-ed-b-fibronektin antikörpern | |
| MX2007007259A (es) | Inhibidores de homodimerizacion de myd88. | |
| WO2007089334A3 (en) | Assay for parkinson's disease therapeutics and enzymatically active parkin preparations useful therein | |
| EA200801174A1 (ru) | Антитела-миметики glp-2, полипептиды, композиции, способы и применения | |
| ATE306498T1 (de) | Von zellen präsentierte peptide | |
| MXPA05011085A (es) | Composiciones y metodos relacionados a stop-1. | |
| ATE497976T1 (de) | Spezifisch an vygfvracl-hla-a24 bindende t-zellen-rezeptoren | |
| DE602006017882D1 (de) | Zusammensetzungen und verfahren zur erhöhung der produktion rekombinanter gamma-carboxylierter proteine | |
| WO2006079057A3 (en) | Methods and compositions for specific inhibition of protein splicing by small molecules | |
| BR122018077204B8 (pt) | peptídeos da proteína humana de estresse térmico, composição farmacêutica, e, uso do peptídeo e da composição farmacêutica |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |